Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1993-01-11
1995-06-27
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514557, A61K 31215, A61K 3119
Patent
active
054280699
ABSTRACT:
The use of a compound possessing functional antagonist properties at the NMDA receptor complex through a specific action at the associated strychnine-insensitive glycine site to improve cognition in normal humans and to treat cognitive deficits resulting from chronic neuronal degeneration, acute brain injury, hypoxia, or other neurological disorders is provided. The compounds possessing functional antagonist properties comprise 1-aminocyclopropanecarboxylic acid, and its pharmaceutically acceptable esters, salts, and acid addition salts or 7-chlorokynurenic acid, and its pharmaceutically acceptable esters, amides, salts, ethers, and acid addition salts.
REFERENCES:
patent: 4570014 (1986-02-01), Schroder et al.
patent: 4781927 (1988-11-01), Zanno et al.
patent: 4788332 (1988-11-01), Zanno et al.
patent: 4822653 (1989-04-01), Zanno et al.
patent: 5086072 (1992-02-01), Trullas et al.
Jones, et al., "Effects of NMDA Modulation in Scopolamine Dementia," 1991, Annals of the New York Academy of Sciences, 640:241-244.
Watson, et al., "Pharmacological Characteristics of Cyclic Homologues of Glycine at the N-Methyl-D-Aspartate Receptor-Associated Glycine Site," 1990, Neuropharmacology, 29(8):727-730.
J. Lehmann, "The NMDA Receptor," 1989, Drugs of the Future, 14(11):1060-1071.
T. W. Stone, "Excitatory Amino Acids," 1992, Current Opinion in Therapeutic Patents, 2(6):907-930.
Rao, et al., "Neuropharmacological Characterization of 1-aminocyclopropane-1-carboxylate and 1-aminocyclobutane-1-carboxylate, Ligands of the N-Methyl-D-Aspartate-Associated Glycine Receptor," 1990, Neuropharmacology, 29(3):305-309.
Wood, et al., "A Glycine Antagonist 7-Chlorokynurenic Acid Attenuates Ischemia-Induced Learning Deficits," 1993, Neuroreport, 4(2):151-154.
Smith, et al., "An NMDA Receptor-Associated Glycine Site Antagonist Attenuates Memory Loss After Experimental Brain Injury," 1990, Soc. Neurosci. Abstr., 16(1):779.
Wood, et al., "7-Chlorokynurenic Acid Reduces CA1 Cell Loss in a Rate Model of Cerebral Ischemia in Vivo," 1991, Soc. Neurosci. Abstr., 17:1265.
Zola-Morgan, et al., "Enduring Memory Impairment in Monkeys After Ischemic Damage to the Hippocampus," 1992, The Journal of Neuroscience, 12(7):2582-2596.
Watanabe, et al., "Involvement of Glycine Site Associated with the NMDA Receptor in Hippocampal Long-Term Potentiation and Acquisition of Spatial Memory in Rats," 1992, Brain Research, 582:58-64.
Ward et al. (1990) Pharm. Biochem. Behavior 35:785-790.
Staubli (1990) Psychobiology 18(3):267-268.
Staubli (1989) Behavioral Neurosci. 103:54-60.
Venable et al. (1990) Psychopharm. 100:215-221.
Sarter et al. (1992) Psychopharm. 107:461-473.
Upchurch et al. (1990) Psychopharm. 100:209-214.
Thompson et al. (1992) Nature 359:638-641.
Oliver et al. (1990) Int. J. Devl. Neurosci. 8(4):417-424.
Mondadori et al. (1992) Psychopharm. 108:11-15.
Chiamulera et al. (1990) Psychopharm. 102:551-552.
Baron et al. (1992) J. Pharmacol. Exp. Ther. 262:947-956.
Clissold et al. (1992) Behavioral Pharmacol. 3:393-402.
Trullas et al. (1991) Eur. J. Pharmacol. Elsevier, pp. 1-7.
Trullas et al. (1990) Eur. J. Pharmacol. Elsevier, pp. 1-10.
DeNoble et al. (1990) Eur. J. Pharmacol. Elsevier, pp. 197-202.
Danysz et al. (1989) Neurosci. Res. Comm. 5(1):9-18.
Mondadori et al. (1989) Exp. Brain Res. 75:449-456.
Wroblewski et al. (1989) Ann. Rev. Pharm. 29:441-474.
Collingridge et al. (1987) Trends Neurosci. 10:228-233.
Collingridge et al. (1983) J. Physiol. 334:33-46.
Artola et al. (1987) Nature 330:649-652.
Kleinschmidt et al. (1987) Science 238:355-358.
Foster et al. (1987) Nature 329:395-396.
Galli et al. (1988) Pharmacol. Res. Comm. 20:407-408.
Bristow et al. (1986) Eur. J. Pharmacol. 126:303-307.
Kemp et al. (1988) Proc. Natl. Acad. Sci. USA 85:6547-6550.
Robinson et al. (1987) FASEB J. 1:446-455.
Hartley et al. (1990) Eur. J. Neurosci. 2:291-295.
Foster et al. (1990) Eur. J. Neurosci. 2:270-277.
Koek et al. (1990) J. Pharmacol. Exp. Ther. 252:349-357.
Skolnick et al. (1989) Life Sci. 45:1647-1655.
Evoniuk et al. (1991) Psychopharm. 105:125-128.
von Lubitz et al. (1992) Eur. J. Pharmacol., in press.
Boje et al. (1992) Brain Res. "Desensitization of the NMDA receptor complex by . . . granule cell cultures" (in press).
Patel et al. (1990) J. Neurochem. 54:849-854.
Faiman Claudia P.
Skolnick Phil
Trullas Ramon
Viu Eugenia
Cintins Marianne M.
Criares T. J.
The United States of America as represented by the Department of
LandOfFree
Treating cognition with, aminocyclopropanecarboxylic derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating cognition with, aminocyclopropanecarboxylic derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating cognition with, aminocyclopropanecarboxylic derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-287978